This amendment proposes to continue DSH payments to Medical Assistance enrolled and qualifying trauma centers. Additionally, it’s updating the qualifying criteria and payment methodology to clarify how new accredited trauma centers and hospitals seeking trauma center accreditation can qualify and be paid.

This plan amendment updates the reimbursement methodology for Medicaid reimbursement for Federally Qualified Health Centers (FQHCs) and Rural Health Centers (RHCs) to reimburse COVID-19 vaccine administration.

CMS is approving this time-limited state plan amendment to respond to the COVID-19 national emergency.  The purpose of this amendment is to waive any signature requirements for the dispensing of drugs during the public health emergency (PHE) from March 13, 2020 through June 30, 2021.

CMS is approving this time-limited state plan amendment to respond to the COVID-19 national emergency.  The purpose of this amendment is to Waive any signature for the dispensing of drugs during the Public Health Emergency through May 1, 2022.

CMS is approving this time-limited state plan amendment to respond to the COVID-19 national emergency.  The purpose of this amendment is to extend the COVID-19 Emergency Sick Leave Benefits for In Home Supportive Services (IHSS) providers through December 31, 2022.

CMS is approving this time-limited state plan amendment to respond to the COVID-19 national emergency.  The purpose of this amendment is to waive any signature requirements for the dispensing of drugs during the Public Health Emergency.

This plan amendment provides clarification for Tribal telehealth.

This SPA clarifies that all vaccine administration services are paid at a rate of $4.00 unless otherwise specified, regardless of billing code. This SPA also sets the state's Monkey Pox vaccine administration rate equal to the Medicare geographic rate for COVID-19 vaccine administration, updating the effective date to 10/15/22 and the fee schedule links for Evaluation & Management Services (E&M) and vaccine administration.

This amendment amends Delaware State Plan to assure coverage of routine patient costs associated with participation in qualifying clinical trials.